Q-omics provides the consensus-scored ACTBP13 profile across patient tissues and cancer cell-line models. ACTBP13 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ACTBP13 is differentially expressed in 8, with the highest sampling consensus in BRCA. Additionally, ACTBP13 RNA expression shows 9,174 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight BLCA, BRCA, and ESCA as cancer lineages where ACTBP13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACTBP13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACTBP13 survival associations across molecular data types. ACTBP13 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACTBP13 RNA expression–survival associations across cancer types. High ACTBP13 expression shows unfavorable associations in LIHC, KIRC, THYM and LUAD, but favorable associations in BLCA and STAD. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for ACTBP13 RNA expression.
This table summarizes ACTBP13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ACTBP13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACTBP13 shows higher tumor expression in BRCA, PAAD, COAD, UCEC, LIHC and STAD. The BRCA box plot shows higher ACTBP13 RNA expression in tumor versus normal tissue (log2 FC = +0.036, t-test p < 0.001).
This table shows molecular features associated with ACTBP13 in patient tissues and cancer cell lines. In patient samples, ACTBP13 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
